Please assess the completion status of the following clinical trial:

Trial Title: Dulcolax vs Placebo in Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients, aged 18 and above~2. Suffering from functional constipation, according to their medical history, as defined by the Rome III diagnostic criteria , i.e.:Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.~   1. Must include 2 or more of the following::~      * straining during at least 25% of the defecations~     * lumpy or hard stools in at least 25% of the defecations~     * sensation of incomplete evacuation for at least 25% of the defecations~     * sensation of anorectal obstruction/blockade for at least 25% of the defecations~     * manual manoeuvres to facilitate at least 25% of the defecations (e.g. digital evacuation, support of the pelvic floor)~     * fewer than 3 defecations per week~  2. Loose stools are rarely present without the use of laxatives~  3. There are insufficient criteria for irritable bowel syndrome (IBS)~3. Able and willing to complete a daily e-diary~4. Able and willing to use the trial rescue medication~5. Signed and dated written informed consent prior to enrolment into the study in accordance with GCP and local legislation~   At Visit 2, patients must comply with the following additional inclusion criteria to be eligible for entry into the treatment phase:~6. Functional constipation is confirmed by e-diary data at the end of the baseline period:~   a. An average of less than 3 CSBMs per week, together with at least one of the following symptoms occurring at least 25% of the time:~  * straining~  * incomplete evacuation~  * lumpy or hard stools (i.e. type 1 or type 2 stools)~7. Compliant with the use of the e-diary throughout the baseline period (compliance is defined as completing 80% of the evening reports)~8. Compliant with the use of rescue medication throughout the baseline period. Compliance is defined as follows:~   * rescue medication may be used if there has not been a bowel movement for more than 72 hrs rescue medication may not be used on either day -1 or on the day of randomisation (day 1)~Exclusion Criteria:~1. Eating disorders such as anorexia nervosa and bulimia, as a cause of excessive use of laxatives~2. Patients whose constipation is caused by primary organic disease of the colon or pelvic floor~3. Patients with metabolic disorders, neurological disorders, severe or psychiatric disorders, or any other significant disease or intercurrent illness (e.g. abdominal/gastrointestinal surgery) that, in the Investigators opinion, would interfere with participation in the trial~4. Patients with restricted mobility (e.g. wheelchair bound, or bed-ridden) that, in the Investigators opinion, would interfere with participation in the trial~5. Patients with a known hypersensitivity to bisacodyl or any other ingredient in the study medication~6. Patients with ileus, intestinal obstruction, acute surgical abdominal conditions (such as acute appendicitis and acute inflammatory bowel diseases), or severe dehydration~7. Patients with anal fissures or ulcerative proctitis with mucosal damage~8. Patients with known clinically significant abnormal electrolyte values~9. Patients whose concomitant therapy includes an opioid medication (e.g. morphine, codeine)~10. Constipation which, in the Investigators opinion, is caused by medication (e.g. anticholinergics)~11. Patients who are not willing to discontinue the use of prohibited concomitant therapy~12. Pre-menopausal women who:~    1. are nursing (breast-feeding) or who are pregnant OR~   2. who are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study. Acceptable methods of birth control include:~       * transdermal patch~      * intra-uterine devices/systems (IUDs/IUSs)~      * oral, implantable or injectable contraceptives~      * sexual abstinence~      * sterilisation or a vasectomised partner~13. Participation in another trial with an investigational product with 1 month of enrolment into this study~14. Drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bisacodyl 5 mg x 2 once daily (Type: EXPERIMENTAL): patient to receive two enteric-coated tablets containing 5 mg bisacodyl
- Placebo (Type: PLACEBO_COMPARATOR): patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl

Based on this trial design, predict the completion outcome and termination type (if applicable).